Wegovy 2.4mg clicks: what the dial tells you and what it doesn't

You've dialled to 2.4mg, here's exactly what that means

Picture the scene: the pen arrives in plain, unbranded packaging via DPD, you put it in the fridge door, and the following morning you take it out and prepare for your injection. The label says 2.4mg. You hear a click as you press the plunger down. That click (and the sensation of the injection completing) tells you the full dose has been delivered. There is no separate measurement step, no syringe to fill, no way to accidentally take more by pressing harder or faster.

Wegovy is a pre-filled, fixed-dose device. Each pen in the 2.4mg box contains exactly 2.4mg of semaglutide per dose. The "click" question most people have is really two questions in one: did I deliver the full dose, and how do I know? The answer to both is the same. Press the plunger fully until it stops moving and hold it against the skin for six seconds. If you want to understand exactly how the 2.4mg Wegovy dose per click works, that page breaks down what each click means and how delivery is confirmed for this specific pen. The Patient Information Leaflet included in your box is also the definitive reference, it describes the exact steps for your pen generation.

One thing worth knowing: the 2.4mg Wegovy pen and the 1.7mg pen before it look similar, and if you are unsure how the click dose on Wegovy is counted and confirmed across different pen sizes, that page explains the detail clearly. Always check the label before injecting. Switching accidentally between doses is the kind of error a quick label-check prevents.

Why 2.4mg is where the titration is designed to land

The reason titration exists is not ceremony. Starting at 0.25mg and stepping up through 0.5mg, 1.0mg and 1.7mg over roughly sixteen weeks gives your digestive system time to adapt to semaglutide's effects. Nausea, bloating and changes in appetite are most pronounced when the dose rises sharply. The gradual schedule reduces how strongly those effects hit. By the time most people reach 2.4mg they have a much clearer picture of how their body responds, and so does their prescriber.

At 2.4mg, STEP 1 trial data showed an average weight reduction of around 15% over 68 weeks alongside lifestyle changes, in adults without diabetes. That figure comes from the STEP 1 trial published in the New England Journal of Medicine, around 1,961 adults, a substantial programme. Individual responses vary. Some people see meaningful results before reaching maintenance; others find 2.4mg is where the effect becomes clearest. A prescriber review at each stage is how adjustments get made safely, which is why clinical oversight doesn't stop once you're established on a dose.

If you want to understand how the 1.7mg step before this one compares, the 1.7mg click guide explains what changes between that pen and the 2.4mg device.

What the 2.4mg click doesn't tell you: side effects and when to act

A completed injection at 2.4mg can bring a step up in side effects for some people, particularly in the first week or two after the dose increase. Nausea is the most commonly reported, along with loose stools, indigestion and, for some, fatigue. These are well-documented in the trial data and in the NHS medicines page for semaglutide. They tend to ease as the body adjusts, usually within days to a couple of weeks.

One symptom that should not be waited out is severe, persistent stomach pain, particularly if it spreads to the back. This can be a sign of pancreatitis, an infrequent but serious reaction. The MHRA highlighted this in a Drug Safety Update in January 2026, specifically for GLP-1 medicines. If this happens, stop the injection and get medical help the same day. You can also report unexpected side effects directly through the MHRA Yellow Card scheme.

Whether side effects get worse as the dose climbs is a question many people ask before they reach 2.4mg. There is a useful breakdown of how the side-effect picture tends to shift across the titration steps on the Wegovy side effects and dosage page, worth reading before your next review.

Where 2.4mg sits in the wider picture: maintenance, higher doses and private access

For most people starting Wegovy, 2.4mg has been the end point of the titration, the maintenance dose. That changed in April 2026 when the MHRA approved a dedicated 7.2mg single-dose pen for adults with a BMI of 30 or above, making it available as the new maximum for those who tolerate and need it. The titration still starts at 0.25mg; 7.2mg is a ceiling reached by clinical progression, not a jump from 2.4mg in one step.

On the NHS, access to Wegovy follows strict eligibility criteria and typically runs through specialist weight management services, with waiting lists that vary considerably by area. Many people pursue a private route instead. For context on what private prescribing involves (including what a legitimate service charges and what that covers) the Wegovy access and cost overview is the place to start. And if cost is part of your thinking, the weight-loss treatment page sets out what a private consultation with our prescribers involves and what the one transparent price includes.

Semaglutide is a prescription-only medicine. Every adjustment, every dose increase and every decision to continue is made by a prescriber who has reviewed your information, not by the click count on a pen. If you have questions about your current dose or whether 2.4mg is still right for you, speaking to a prescriber is the right next step. You can start a free consultation with our clinical team today.